Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action.

Dopamine D(2) receptor antagonism is a unifying property of all antipsychotic drugs in clinical use. Remarkably, the effector molecules through which these medications exert their actions remain poorly characterized. Increasing attention is being focused on Akt/glycogen synthase kinase-3 (GSK-3) and wingless (Wnt) signaling pathways, which have been associated with schizophrenia in a number of genetic and postmortem studies. Antipsychotic medications may treat symptoms of psychosis, at least in part, through modulation of levels and activity of Akt, GSK-3, and Wnt-related intracellular signaling. The authors review evidence that Akt/GSK-3 and Wnt-related pathways are involved in the pathogenesis of schizophrenia as well as details of intracellular events related to these molecules mediated by both typical and atypical antipsychotic medications. Further study of Akt/GSK-3 and Wnt signaling may ultimately lead to alternative therapeutics of schizophrenia-related disorders.

[1]  A Carlsson,et al.  The current status of the dopamine hypothesis of schizophrenia. , 1988, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[2]  N. Swerdlow,et al.  Startle response models of sensorimotor gating and habituation deficits in schizophrenia , 1990, Brain Research Bulletin.

[3]  Andrew P. McMahon,et al.  The Wnt-1 (int-1) proto-oncogene is required for development of a large region of the mouse brain , 1990, Cell.

[4]  Richard Paylor,et al.  Social Interaction and Sensorimotor Gating Abnormalities in Mice Lacking Dvl1 , 1997, Cell.

[5]  S Lovestone,et al.  Abnormalities of Wnt signalling in schizophrenia – evidence for neurodevelopmental abnormality , 1998, Neuroreport.

[6]  Tsuyoshi Miyaoka,et al.  Increased expression of Wnt-1 in schizophrenic brains , 1999, Schizophrenia Research.

[7]  B. Dean.  Signal Transmission, Rather Than Reception, is the Underlying Neurochemical Abnormality in Schizophrenia , 2000, The Australian and New Zealand journal of psychiatry.

[8]  Decreased GSK-3̵ immunoreactivity in postmortem frotal cortex of schizophrenic patients , 2000, European Neuropsychopharmacology.

[9]  J. Cohen,et al.  Relation of prefrontal cortex dysfunction to working memory and symptoms in schizophrenia. , 2001, The American journal of psychiatry.

[10]  P. Gean,et al.  A Role for the PI-3 Kinase Signaling Pathway in Fear Conditioning and Synaptic Plasticity in the Amygdala , 2001, Neuron.

[11]  R. Belmaker,et al.  Low GSK-3 activity in frontal cortex of schizophrenic patients , 2001, Schizophrenia Research.

[12]  S. Fukumoto,et al.  Akt Participation in the Wnt Signaling Pathway through Dishevelled* , 2001, The Journal of Biological Chemistry.

[13]  R. V. Van Heertum,et al.  Prefrontal Dopamine D1 Receptors and Working Memory in Schizophrenia , 2002, The Journal of Neuroscience.

[14]  S. Sealfon,et al.  Agonist-specific Transactivation of Phosphoinositide 3-Kinase Signaling Pathway Mediated by the Dopamine D2 Receptor* , 2003, Journal of Biological Chemistry.

[15]  B. Doble,et al.  GSK-3: tricks of the trade for a multi-tasking kinase , 2003, Journal of Cell Science.

[16]  Hongyan Zhang,et al.  Association study of the human FZD3 locus with schizophrenia , 2003, Biological Psychiatry.

[17]  Xin Yu,et al.  Positive association of the human frizzled 3 (FZD3) gene haplotype with schizophrenia in Chinese Han population , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[18]  U. Kang,et al.  The effects of clozapine on the GSK‐3‐mediated signaling pathway , 2004, FEBS letters.

[19]  H. Manji,et al.  AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. , 2004, The international journal of neuropsychopharmacology.

[20]  M. Tateno,et al.  Neurotoxic potential of haloperidol in comparison with risperidone: implication of Akt-mediated signal changes by haloperidol , 2004, Journal of Neural Transmission.

[21]  M. Karayiorgou,et al.  Convergent evidence for impaired AKT1-GSK3β signaling in schizophrenia , 2004, Nature Genetics.

[22]  H. Manji,et al.  AR-A 014418 , a selective GSK-3 inhibitor , produces antidepressant-like effects in the forced swim test , 2004 .

[23]  T. Sotnikova,et al.  Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[24]  K. Marumo,et al.  Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN‐mutated prostate cancer cells , 2005, The Prostate.

[25]  T. Sotnikova,et al.  An Akt/β-Arrestin 2/PP2A Signaling Complex Mediates Dopaminergic Neurotransmission and Behavior , 2005, Cell.

[26]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[27]  J. Javitch,et al.  Akt Is Essential for Insulin Modulation of Amphetamine-Induced Human Dopamine Transporter Cell-Surface Redistribution , 2005, Molecular Pharmacology.

[28]  J. Frahm,et al.  Essential role of protein kinase Bγ (PKBγ/Akt3) in postnatal brain development but not in glucose homeostasis , 2005, Development.

[29]  N. Rajakumar,et al.  The effects of antipsychotics on β‐catenin, glycogen synthase kinase‐3 and dishevelled in the ventral midbrain of rats , 2005, Journal of neurochemistry.

[30]  P. Pavlidis,et al.  Akt1 deficiency affects neuronal morphology and predisposes to abnormalities in prefrontal cortex functioning , 2006, Proceedings of the National Academy of Sciences.

[31]  T. Steckler,et al.  Transgenic Mice Overexpressing Glycogen Synthase Kinase 3β: A Putative Model of Hyperactivity and Mania , 2006, The Journal of Neuroscience.

[32]  Haloperidol induces apoptosis via the sigma2 receptor system and Bcl-XS. , 2006, The pharmacogenomics journal.

[33]  B. Doble,et al.  Glycogen synthase kinase-3--an overview of an over-achieving protein kinase. , 2006, Current drug targets.

[34]  David L. Roberts,et al.  The functional significance of social cognition in schizophrenia: a review. , 2006, Schizophrenia bulletin.

[35]  Y. Ahn,et al.  Haloperidol and clozapine differentially regulate signals upstream of glycogen synthase kinase 3 in the rat frontal cortex , 2007, Experimental & Molecular Medicine.

[36]  R. Gainetdinov,et al.  The Akt-GSK-3 signaling cascade in the actions of dopamine. , 2007, Trends in pharmacological sciences.

[37]  Jürgen Gallinat,et al.  Molecular Mechanisms of Schizophrenia , 2007, Cellular Physiology and Biochemistry.

[38]  Sheng Li,et al.  Association of AKT1 gene polymorphisms with risk of schizophrenia and with response to antipsychotics in the Chinese population. , 2007, The Journal of clinical psychiatry.

[39]  J. Javitch,et al.  D2 Receptors Regulate Dopamine Transporter Function via an Extracellular Signal-Regulated Kinases 1 and 2-Dependent and Phosphoinositide 3 Kinase-Independent Mechanism , 2007, Molecular Pharmacology.

[40]  N. Rajakumar,et al.  Activation of the canonical Wnt pathway by the antipsychotics haloperidol and clozapine involves dishevelled‐3 , 2007, Journal of neurochemistry.

[41]  J. Lieberman,et al.  AKT1 and Neurocognition in Schizophrenia , 2007, The Australian and New Zealand journal of psychiatry.

[42]  T. Sotnikova,et al.  Regulation of Akt Signaling by D2 and D3 Dopamine Receptors In Vivo , 2007, The Journal of Neuroscience.

[43]  D. Theobald,et al.  IRS2-Akt pathway in midbrain dopamine neurons regulates behavioral and cellular responses to opiates , 2007, Nature Neuroscience.

[44]  M. D. Forti,et al.  Schizophrenia as a GSK-3 dysregulation disorder , 2007, Trends in Neurosciences.

[45]  Anirvan Ghosh,et al.  Should I Stay or Should I Go: Wnt Signals at the Synapse , 2007, Cell.

[46]  D. V. Vactor,et al.  Synapse Specificity: Wnts Keep Motor Axons on Target , 2007, Current Biology.

[47]  B. Hemmings,et al.  Physiological roles of PKB/Akt isoforms in development and disease. , 2007, Biochemical Society transactions.

[48]  D. Mousseau,et al.  Haloperidol induces the nuclear translocation of phosphatidylinositol 3'-kinase to disrupt Akt phosphorylation in PC12 cells. , 2007, Journal of psychiatry & neuroscience : JPN.

[49]  Jing Wang,et al.  Role of the phosphoinositide 3-kinase-Akt-mammalian target of the rapamycin signaling pathway in long-term potentiation and trace fear conditioning memory in rat medial prefrontal cortex. , 2008, Learning & memory.

[50]  Francis J McMahon,et al.  Association study of Wnt signaling pathway genes in bipolar disorder. , 2008, Archives of general psychiatry.

[51]  R. Gainetdinov,et al.  Antagonism of dopamine D2 receptor/β-arrestin 2 interaction is a common property of clinically effective antipsychotics , 2008, Proceedings of the National Academy of Sciences.

[52]  Francis J McMahon,et al.  Gene‐based SNP mapping of a psychotic bipolar affective disorder linkage region on 22q12.3: Association with HMG2L1 and TOM1 , 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[53]  Vladimir I. Vladimirov,et al.  AKT1 Is Associated with Schizophrenia Across Multiple Symptom Dimensions in the Irish Study of High Density Schizophrenia Families , 2008, Biological Psychiatry.

[54]  T. Franke,et al.  PI3K/Akt: getting it right matters , 2008, Oncogene.

[55]  G. Collingridge,et al.  The role of GSK‐3 in synaptic plasticity , 2008, British journal of pharmacology.

[56]  K. Takemaru,et al.  Chibby cooperates with 14-3-3 to regulate β-catenin subcellular distribution and signaling activity , 2008, The Journal of cell biology.

[57]  A. Meyer-Lindenberg,et al.  Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans. , 2008, The Journal of clinical investigation.

[58]  J. Javitch,et al.  Recruitment of β-arrestin2 to the dopamine D2 receptor: Insights into anti-psychotic and anti-parkinsonian drug receptor signaling , 2008, Neuropharmacology.

[59]  R. Rodriguiz,et al.  A β-arrestin 2 Signaling Complex Mediates Lithium Action on Behavior , 2008, Cell.

[60]  Li-Huei Tsai,et al.  Disrupted in Schizophrenia 1 Regulates Neuronal Progenitor Proliferation via Modulation of GSK3β/β-Catenin Signaling , 2009, Cell.

[61]  P. Chan,et al.  Oxidative stress and mitochondrial dysfunction as determinants of ischemic neuronal death and survival , 2009, Journal of neurochemistry.

[62]  T. McGraw,et al.  Insulin-modulated Akt subcellular localization determines Akt isoform-specific signaling , 2009, Proceedings of the National Academy of Sciences.

[63]  Amy Baohan,et al.  Regulation of the postnatal development of dopamine neurons of the substantia nigra in vivo by Akt/protein kinase B , 2009, Journal of neurochemistry.

[64]  Christer Halldin,et al.  Arrestin3 mediates D2 dopamine receptor internalization , 2009, Synapse.

[65]  B. Manning,et al.  A complex interplay between Akt, TSC2 and the two mTOR complexes. , 2009, Biochemical Society transactions.